NasdaqGS:TEMLife Sciences
Tempus AI (TEM): Evaluating Valuation After FDA Clearance Boosts Cardiac Imaging Expansion
Tempus AI (TEM) just grabbed the spotlight after receiving 510(k) clearance from the U.S. Food and Drug Administration for its upgraded Tempus Pixel cardiac imaging platform. This green light means Tempus can officially bring its AI-powered cardiac imaging updates, including new T1 and T2 inline mapping, into clinics, putting the company firmly on the map in cardiology alongside its oncology roots. For investors wondering what this means, FDA clearance is not just a regulatory formality; it...